icons icons icons
Dietetics

23.05.2025

Iron deficiency anemia in cystic fibrosis.

Prevalence and causes:

Iron deficiency anemia is more common in patients with cystic fibrosis (CF), especially as lung disease progresses.

Causes of deficiency include:
• respiratory iron loss (sputum),
• gastrointestinal iron loss,
• chronic inflammation that affects iron metabolism.

Infections:

Despite the association between iron and bacteria (especially Pseudomonas aeruginosa), studies have not found worsening of lung function or increased exacerbations with oral iron.

Diagnosis:

Evaluation of iron levels is complicated by the influence of inflammation on laboratory markers:
• ferritin may be elevated due to inflammation, even in the presence of iron deficiency;
• transferrin and transferrin saturation are decreased;
• C-reactive protein (CRP) is recommended for correct interpretation.

Optimal limits:

• <12 ng/mL ferritin (classic WHO limit) — not sensitive enough in CF;
• <30 ng/mL — reasonable limit in chronic inflammation;
• <45 ng/mL — recommended by the American Gastroenterological Association for anemia.

Treatment:

• First-line treatment — oral iron:
• adults: 150–200 mg elemental iron/day;
• children: 3–6 mg/kg/day (in 2–3 divided doses).
• Gastrointestinal intolerance is common.
• New studies support lower or alternate-day doses for better tolerability and absorption.
• Hepcidin — a hormone that regulates iron metabolism — increases after iron ingestion (especially ≥60 mg) and reduces its further absorption over the next 24 hours.

Additional factors:

• Vitamin C improves iron absorption;
• Calcium, phytates (cereals), tannins (tea) — reduce.
• Intravenous iron administration is possible in case of intolerance, but its effectiveness and safety in CF require additional study.

Current problems:

• Lack of unified protocols for screening, diagnosis and treatment of iron deficiency in CF.
• Difficulties in differentiating between anemia of chronic disease and true iron deficiency.
• Some doctors fear that iron may stimulate the growth of bacteria, although there is no scientific evidence for this.

POPULAR NEWS

image

Marta Sheremet – Co-author of an International Publication

image

Ukraine at the 49th European Cystic Fibrosis Conference

image

ECFS 2026: New Horizons in Cystic Fibrosis Treatment

image

49th EUROPEAN CYSTIC FIBROSIS CONFERENCE. LISBON, PORTUGAL

image

Strengthening the representation of rare disease patients in the Ministry of Health

image

Charitable Projects Support Program 2026